- Home
- TNGX vs QLYS Comparison
TNGX vs QLYS Comparison
Compare TNGX & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | QLYS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TNGX | QLYS |
|---|---|---|
| Price | $19.77 | $98.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 13 |
| Target Price | $21.78 | ★ $133.08 |
| AVG Volume (30 Days) | ★ 2.6M | 756.7K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | 16.99 |
| EPS | N/A | ★ 1.42 |
| Revenue | $62,384,000.00 | ★ $321,607,000.00 |
| Revenue This Year | N/A | $9.97 |
| Revenue Next Year | N/A | $7.15 |
| P/E Ratio | ★ N/A | $72.23 |
| Revenue Growth | ★ 48.29 | 15.32 |
| 52 Week Low | $1.93 | $74.51 |
| 52 Week High | $28.41 | $155.47 |
Technical Indicators
Market Signals| Indicator | TNGX | QLYS |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 58.36 |
| Support Level | $7.08 | $83.94 |
| Resistance Level | $22.01 | $102.25 |
| Average True Range (ATR) | 1.71 | 4.46 |
| MACD | -0.49 | 1.03 |
| Stochastic Oscillator | 4.88 | 70.31 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.